INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support  by Li, Jun et al.
INCB16562, a JAK1/2 Selective
Inhibitor, Is Efficacious against
Multiple Myeloma Cells and
Reverses the Protective Effects of
Cytokine and Stromal Cell Support
Jun Li, Margaret Favata, Jennifer A. Kelley,
Eian Caulder, Beth Thomas, Xiaoming Wen,
Richard B. Sparks, Ari Arvanitis,
James D. Rogers, Andrew P. Combs, Kris Vaddi,
Kimberly A. Solomon, Peggy A. Scherle,
Robert Newton and Jordan S. Fridman
Discovery Biology, Incyte Corporation, Wilmington, DE, USA
Abstract
Cytokines in the bone marrow of multiple myeloma patients activate Janus kinase (JAK)/signal transducer and activa-
tor of transcription (STAT) signaling pathways in tumor cells and promote tumor growth, survival, and drug resistance.
INCB16562 was developed as a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2
markedly selective over JAK3. The specific cellular activity of the inhibitor was demonstrated by its potent and
dose-dependent inhibition of cytokine-dependent JAK/STAT signaling and cell proliferation in the absence of effects
on Bcr-Abl–expressing cells. Treatment of myeloma cells with INCB16562 potently inhibited interleukin-6 (IL-6)–
induced phosphorylation of STAT3. Moreover, the proliferation and survival of myeloma cells dependent on IL-6 for
growth, as well as the IL-6–induced growth of primary bone marrow–derived plasma cells from a multiple myeloma
patient, were inhibited by INCB16562. Induction of caspase activation and apoptosis was observed and attributed, at
least in part, to the suppression of Mcl-1 expression. Importantly, INCB16562 abrogated the protective effects of re-
combinant cytokines or bone marrow stromal cells and sensitized myeloma cells to cell death by exposure to dexa-
methasone, melphalan, or bortezomib. Oral administration of INCB16562 antagonized the growth of myeloma
xenografts in mice and enhanced the antitumor activity of relevant agents in combination studies. Taken together,
these data suggest that INCB16562 is a potent JAK1/2 inhibitor and that mitigation of JAK/STAT signaling by targeting
JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents.
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Introduction
Multiple myeloma (MM or myeloma) is a clonal malignant B-cell
disorder characterized by the accumulation of malignant plasma cells
in the bone marrow, leading to osteolytic bone destruction and im-
paired hematopoiesis. MM accounts for approximately 10% of all
hematologic cancers, and it is estimated that approximately 20,000
new cases will be diagnosed and that more than 10,000 patients will
succumb to the disease annually in the United States alone [1]. Despite
recent progress in the treatment of MM, there is still no cure for this
disease, and most patients eventually develop advanced, relapsing dis-
ease that is resistant to the drug(s) to which they have had prolonged
exposure. Therefore, new treatment approaches and novel drug combi-
nations are needed [2].
The development and progression of MM is dependent on a variety
of different cytokines that support myeloma cell proliferation in the
bone marrow microenvironment. Cytokines released by bone marrow
stromal cells (BMSCs) and/or MM cells that have been described to
have this supportive potential include interleukin-6 (IL-6), vascular
endothelial growth factor (VEGF), insulin-like growth factor-1, basic
fibroblast growth factor, IL-1, IL-10, IL-11, IL-15, IL-21, granulocyte
macrophage colony-stimulation factor (GM-CSF), interferon-α, and
leukemia inhibitory factor [3]. Among these cytokines, IL-6 has been
most widely studied and is considered to play a pivotal role as a growth
and survival factor for myeloma cells [4–7]. Evidence indicates that ele-
vated IL-6 expression in the tumor microenvironment may be a major
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factor leading to drug resistance [8–10]. It is believed that BMSCs are
a major source of IL-6 for the myeloma cells; however, the interaction
between myeloma cells and BMSCs may be multifactorial [11,12].
Binding of IL-6 to the IL-6 receptor (IL-6R) on the myeloma cell sur-
face induces dimerization with gp130 and activation of the receptor-
associated Janus kinase (JAK) tyrosine kinases, JAK1, JAK2, and Tyk2
[13,14]. The activated JAKs trigger the phosphorylation of IL-6R and
gp130, followed by activation of a number of downstream signaling
molecules including signal transducer and activator of transcription-3
(STAT3), mitogen-activated protein kinase (MAPK), and Akt, thereby
fostering the growth and/or survival of myeloma cells [13,15]. Similar
to IL-6 signaling, the JAKs can be activated by many of the cytokines
mentioned above whose receptors lack intrinsic kinase activity and
therefore use the JAKs to transmit their extracellular signal into an intra-
cellular response [16]. JAKs can also be aberrantly activated by either
mutation, such as the JAK2V617Fmutation that is found in myelopro-
liferative disease (MPD) or epigenetic inactivation of negative regulators
such as SOCS1/3 and SHP-1 [17,18]. Regarding the latter, hypermeth-
ylation of SOCS1/3 and SHP-1 have been recently found in 63% and
80% of myeloma patients, respectively [19,20]. In addition, VEGF has
been recently shown to play an important role in MM development.
Although no JAK is directly associated with the VEGF receptor, it has
been shown that IL-6 may be involved in promoting secretion of VEGF
byMMcells and BMSCs [21]. Because the JAKs play critical roles in the
signal transduction of IL-6 and many other cytokines that may be in-
volved in promoting MM development, blockade of JAK signaling
should diminish the supportive effects of aberrant JAK signaling in
myeloma cells. Pharmacological inhibition of JAKs may therefore be a
promising therapeutic strategy for treatment of myeloma.
We previously described the effects of INCB20, a pan-JAK inhibitor,
in models relevant to MM [22]. However, INCB20 inhibits all JAK
family members at similar potencies [22]. One concern of using such
compounds is that inhibition of JAK3may cause severe and undesirable
immunosuppression in a patient population with an already compro-
mised bone marrow function [23]. In addition, the pharmaceutical
properties of INCB20 precluded oral dosing of animals. The present
study describes a novel, orally bioavailable, and ATP-competitive
JAK1/2 inhibitor, INCB16562, with potent enzyme and cellular ac-
tivity. This compound is markedly selective for JAK1/2 over JAK3
and potently inhibits JAK/STATsignaling in a number of myeloma cell
lines as well as primary MM cells. Moreover, INCB16562 affects the
viability of IL-6–dependent myeloma cells in culture and in vivo by
inducing caspase activation and apoptosis. For the first time, we show
that selective JAK1/2 inhibition potentiates the effects of a variety of
relevant therapeutics by mitigating the protective effects of IL-6 and
the tumor microenvironment in tissue culture models and in vivo.
Materials and Methods
Kinase Enzyme Assays
INCB16562, as a novel JAK inhibitor, was discovered and synthe-
sized at Incyte. Its ability to inhibit the activity of kinases of the JAK
family wasmeasured using in vitro enzyme assays as previously described
[22]. Briefly, the enzymes used in the assays were partially purified and
N-terminal FLAG-tagged recombinant proteins consisting of the cata-
lytic domains of human JAK1, JAK2, JAK3, or Tyk2. These enzymes
catalyzed the phosphorylation of the peptide biotin-EQEDEPEGDY-
FEWLE and theHTRF fluorescent signal was then measured on a plate
reader. The IC50 was calculated and reported as the compound con-
centration required for inhibition of 50% of the fluorescent signal.
The ATP concentrations used in each enzyme reactions were 90, 30,
3, and 20μMfor JAK1, JAK2, JAK3, and Tyk2, respectively, equivalent
to the Km for ATP for the corresponding enzyme. Assays were also
conducted using an ATP concentration of 1 mM comparable to cellular
levels of ATP, on JAK1, JAK2, and JAK3 to confirm the selectivity of
INCB16562 among the JAK family members. To determine the selec-
tivity of INCB16562 against other kinases, the compound was tested
at a concentration of 100 nM for the ability to inhibit kinase activities
of a commercial panel of 36 protein kinases at Upstate (Charlottesville,
VA). The results were calculated and listed in Table 2.
Cell Culture
Human MM cell lines H929, U266, and RPMI8226 were pur-
chased from the American Type Culture Collection (ATCC, Rockville,
MD), and Dex-sensitive MM1.S and IL-6–dependent INA-6 cell lines
were kindly provided by Dr. R. Burger [24] (Dana-Farber Cancer
Institute, Boston, MA). A complete medium of RPMI 1640 supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine was used to maintain these cell
lines at 37°C in 5% CO2 atmosphere. For INA-6 only, 1 ng/ml of hu-
man recombinant IL-6 (R&D System, Minneapolis, MN) was added
to the medium. The parental cytokine dependent human erythro-
leukemic cell line TF-1 was obtained from ATCC, and a cytokine-
independent TF-1–Bcr-Abl cell line was developed by transfection
and stable overexpression of the human Bcr-Abl gene in the TF-1 cells.
Both cells were cultured in the same medium with the added presence
of 2 ng/ml human granulocyte macrophage colony-stimulating factor
(GM-CSF) (R&D System) for the TF-1 cell culture. Primary bone
marrow CD138+ plasma cells from a newly diagnosed MM patient
were purchased fromAllcells (Emeryville, CA). The cells were cultured
in the same medium used for above MM cells based on the protocol
suggested by the manufacturer. Human BMSCs were purchased from
Cambrex (Walkersville, MD) and initially grown in a Dulbecco’s
modified Eagle medium containing 20% fetal bovine serum, 1 mM
Na-pyruvate (Hyclone, Logan, UT), 1 ng/ml epidermal growth fac-
tor (R&D System), and 2 mM L-glutamine. The medium was then
switched to the same medium used for MM cells in experiments.
Cell Viability Assay
Suspensions of INA-6, TF-1, TF-1–Bcr-Abl, U266, H929,
RPMI8226, MM1.S, or primary CD138+ plasma cells in medium
supplemented with 1 ng/ml IL-6 for INA-6 or 2 ng/ml of GM-CSF
for TF-1 were equally distributed into 96-well flat-bottomed plates.
Triplicate wells were treated with INCB16562 at various concentra-
tions or DMSO (Sigma, St. Louis, MO) as control. Plates were in-
cubated at 37°C in 5% CO2 atmosphere for 72 hours. Cell viability
or proliferation was measured using the CellTiter-Glo (Promega,
Madison, WI) reagent according to the manufacturer’s protocol or
using Trypan blue exclusion tests. The IC50 was calculated as the com-
pound concentration to inhibit 50% of the signal from DMSO-treated
cells, and the percent inhibition of growth was also calculated relative to
DMSO-treated cells.
Proliferation Assay in Coculture with Bone Marrow
Stromal Cells
Stromal cells were seeded in flat bottom 96-well culture plates at
confluence in the RPMI 1640 medium and incubated for 1 day.
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INA-6 or MM1.S cells were added to the stromal cells in the same
medium. Dexamethasone (Sigma), melphalan (Sigma), bortezomib
(Millennium Pharmaceuticals, Cambridge, MA), and INCB16562,
either as single compound or in combination, were then added at the
final concentrations indicated in the corresponding figures. The plates
were incubated at 37°C in 5% CO2 atmosphere for 72 hours, and then
0.25 μCi of [3H]-thymidine (PerkinElmer, Boston, MA) per well was
added and incubated for an additional 7 hours. The cultures were
harvested onto GF-B 96-well filter plates using a FilterMate Harvester
(PerkinElmer). Incorporated radioactivity was counted on a TopCount
NXT (PerkinElmer) with the scintillant MicroScint-20 (PerkinElmer).
The percent inhibition of cell growth was calculated based on the nega-
tive control, the DMSO-treated cells.
Cell Cycle Analysis
Cell cycle distribution was determined by staining cells with propi-
dium iodide (PI; BD Biosciences, Franklin Lakes, NJ). Briefly, INA-6
cells were equally distributed into six-well plates in medium in the pres-
ence of 1 ng/ml of IL-6. Cells were treated with either INCB16562 at
800 nM or an equal volume of DMSO and then incubated at 37°C
in 5% CO2 atmosphere for 20 hours. Approximately 1 × 10
6 cells
were collected and fixed in 70% ethanol and then stained with PI for
30 minutes at room temperature according to the manufacturer’s pro-
tocol. The percentage of cells in the different phases of the cell cycle was
analyzed using a FACSCalibur flow cytometer (BD Biosciences).
Apoptosis Analysis
INCB16562-induced apoptosis in INA-6 cells was assayed by
annexin V/PI staining and caspase activation. Cells were equally dis-
tributed into 6-well or 96-well culture plates in medium in the pres-
ence of 1 ng/ml of IL-6. Cells were treated with INCB16562 at
various concentrations as indicated in the figures or with DMSO
as a control and then incubated at 37°C in 5% CO2 atmosphere for
24 hours. For annexin V/PI staining, an aliquot of cells was removed
from the six-well plate and stained with annexin V–fluorescein isothio-
cyanate and PI according to the manufacturer’s directions (Apoptosis
Detection Kit; Sigma) and analyzed using a FACSCalibur flow cyto-
meter (BD Biosciences). For caspase activation assays, cell lysis reagents
and specific substrates of caspase-3/7, caspase-8, or caspase-9 were di-
rectly added into cell cultures in the 96-well plates, and the fluorescent
signals (RFLU) of rhodamine-110 groups released from the substrates
on activation of caspases were analyzed based on the manufacturer’s
protocols (Promega).
Western Blot Analysis
Cells were treated with INCB16562 or DMSO at concentrations
and for periods as indicated in the figures. After treatment, cells were
washed with ice-cold PBS and resuspended in a cell extraction buffer
(Invitrogen, Carlsbad, CA) and lysed based on the manufacturer’s
protocols. Equivalent amounts of protein (∼70 μg) from each lysate
were resolved in 4% to 12% SDS-PAGE (Invitrogen) and transferred to
polyvinylidene difluoride membranes (Invitrogen). The primary anti-
bodies specific for the following proteins were used at the indicated di-
lutions: phospho-STAT3 (1:1000), STAT3 (1:1000), STAT5 (1:1000),
phospho-JAK2 (1:1000), and JAK2 (1:1000; all from Cell Signaling,
Beverly, MA); phospho-STAT5 (1:1000; Millipore, Temecula, CA);
Mcl-1 (1:100), poly (ADP-ribose) polymerase (PARP; 1:100), Bcl-2
(1:100), Bcl-XL (1:100), β-actin (1:100; all from Santa Cruz Biotech-
nology, Santa Cruz, CA). After incubating with the antibody, the im-
munoreactive bands were detected with a chemiluminescent substrate
(SuperSignal; Pierce, Rockford, IL).
Tumor Xenografts
Animal studies were performed under Animal Welfare Regulation
Guidelines in a facility at theDuPont Experimental Station,Wilmington,
DE, accredited by the Association for the Assessment and Accredita-
tion of Laboratory Animal Care. Studies were performed as described
previously [22]. Briefly, 6- to 8-week-old severe combined immu-
nodeficient mice (Charles River, Wilmington, MA) were injected sub-
cutaneously with approximately 1 × 106 viable INA-6.Tu1 cells freshly
harvested from a tumor-bearing mouse. Animals were monitored daily
for signs of tumor growth andmeasured with calipers two to three times
each week after visible tumor was detected. Tumor volume was calcu-
lated as (length × width2) / 2. When tumors were well established
(>125 mm3), animals were assigned into treatment groups with similar
median tumor volumes. Mice were dosed orally, twice daily, with ve-
hicle (0.5% methocellulose and 5% N ,N -dimethylacetamide) or
INCB16562. Melphalan and bortezomib were formulated in sterile
saline and were dosed twice each week, i.p., beginning 3 days after
onset of treatment with INCB16562. Animals were weighed regularly
to adjust dose levels and to monitor for gross signs of toxicity. Percent
tumor growth inhibition was calculated as follows: [1 − (mean tumor
volume, treated group ÷ mean tumor volume, vehicle group)] × 100.
Statistical significance between mean tumor volumes in various treat-
ment groups was assessed using Student’s t test.
Results
Enzymatic Potency of INCB16562
The biochemical potency of INCB16562 (Figure 1) for the inhibi-
tion of JAKs was determined in enzymatic assays using recombinant
proteins containing the catalytic domain of each human JAK family
member. Assays were conducted at an ATP concentration equivalent
to the K m for each enzyme. INCB16562 was determined to be a
low-nanomolar inhibitor of JAKs with IC50 values of 2.2, 0.25, 10.1,
and 2.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively (Table 1).
Because this inhibitor was found to be a reversible ATP-competitive
kinase inhibitor (unpublished data), the calculated IC50 values taking
into account the high concentration of ATP in cells (using 1 mM ATP
as typical of the cell concentration [25]) predict that this compound
would have a relative selectivity for JAK2 and JAK1 over TYK2 and
a marked selectivity over JAK3 inside cells. This predicted selectivity
Figure 1. Chemical structure of INCB16562.
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of JAK1/2 over JAK3 was experimentally confirmed by running enzy-
matic assays at 1 mM ATP concentration (Table 1).
To more broadly characterize the selectivity of INCB16562 among
other human kinases, we tested this compound against a commercial
panel of 36 kinases at 100 nM, a concentration approximately 75×
the average IC50 value for JAK1 and JAK2 (Table 2). INCB16562
demonstrated no significant inhibition (<20% inhibition) for most of
the kinases tested. Modest inhibitory effects (36%-54%) against Lck,
Aurora-A, and Alk kinases were observed at this relatively high concen-
tration of inhibitor.
Cellular Effects of INCB16562
Whereas IL-6 has been implicated in the pathogenesis of myeloma,
the reliance of established myeloma cell cultures on exogenous cyto-
kines may not be conserved, depending on the culture conditions used
to establish and maintain them [26]. Therefore, we analyzed the effects
of INCB16562 in both cytokine-dependent and cytokine-responsive
myeloma cells. We first chose the human INA-6 MM cell line to study
the effects of INCB16562 on JAK1 and/or JAK2 activities because
these cells require exogenous IL-6 for in vitro growth and survival
[24]. It has been previously demonstrated that activation of JAK/STAT3
in these cells is dependent on the presence of IL-6 and inactivation of
JAK/STAT3 by either withdrawal of IL-6 or prevention of IL-6 binding
to the receptor induces cell death through apoptosis [27]. Moreover,
using a commercially available pan-JAK inhibitor, these cells have been
shown to be responsive to JAK inhibition that results in a concordant
reduction in the levels of phosphorylated STAT3 (p-STAT3) [28].
Therefore, the cellular activity of INCB16562 could be assessed by
examining inhibition of STAT3 phosphorylation and cell growth in
INA-6 cells. As shown in Figure 2A, the compound potently inhibited
STAT3 phosphorylation with almost complete inhibition at concentra-
tions of 300 nM or greater. As a control, the total STAT3 level was not
significantly changed. Because INA-6 cells require JAK activating cyto-
kines for survival, we determined the effects of INCB16562 on the
viable number of cells during a 3-day period. A dose-dependent reduc-
tion in viable cells was observed with an average IC50 of 191 ± 50 nM
(Figure 2B), consistent with the observed potency on STAT3 phosphor-
ylation. In addition, we also measured the potency shift of INCB16562
in response to the addition of different concentrations (0.5-100 ng/ml)
of IL-6 to INA-6 cells, considering the variation of IL-6 concentrations
in the BM microenvironments of MM patients. As assessed by STAT3
phosphorylation and cell proliferation, higher concentrations of IL-6 did
cause a rightward shift in IC50 value when compared with lower concen-
trations. However, the fold shift was small and within a two-fold varia-
tion range (data not shown), suggesting that this compound should
remain potent even in the presence of very high concentrations of
IL-6, and this effect should be extended to other cytokines as well.
The ability of INCB16562 to inhibit JAK/STAT3 activation in mye-
loma cells was confirmed using a panel of cell lines that have been se-
lected for IL-6 independence but remain cytokine responsive: MM1.S,
H929, U266, and RPMI8226. Each of these cell lines demonstrated
robust activation of JAK signaling on addition of IL-6, as shown by
markedly increased levels of p-STAT3 (Figure 2C ). Importantly,
INCB16562 potently and dose-dependently reduced p-STAT3 levels
stimulated by IL-6 in all these cell lines without affecting the total
STAT3 present in these cells. Possibly because of the higher intracellular
ATP levels, higher concentrations of INCB16562were required to com-
pletely inhibit the STAT3 phosphorylation in some cell lines. Although
remaining IL-6–responsive, the growth of these cells was not signifi-
cantly affected by exogenously added IL-6 (data not shown). To evaluate
any effects of INCB16562 on the growth of these cell lines, cells were
incubated with the compound at pharmacologically active concentra-
tions in regular culture medium for 3 days, and the cell viability was
analyzed. It was found that INCB16562 did not inhibit the growth
of MM1.S, RPMI8226, and H929 cells, but it partially inhibited the
growth of U266 cells (Figure 2D). The data are consistent with previous
reports that the growth of U266, but not the other three cell lines, is
partially dependent on JAK/STAT activation through the autocrine
IL-6 signaling pathway [28,29].
The cellular activity of INCB16562 was also examined in primary
CD138+ plasma cells from the bone marrow of a newly diagnosed
MM patient. The primary cells were incubated with INCB16562 at
various concentrations in the absence or presence of IL-6 for 3 days,
Table 1. INCB16562 Is a Potent JAK1/2 Inhibitor.
Enzyme IC50 (nM)* (ATP = Km) IC50 (nM)
† (ATP = 1 mM)
JAK1 2.2 ± 0.77 9.1 ± 2.5
JAK2 0.25 ± 0.17 2.1 ± 1.1
JAK3 10.1 ± 3.6 1663 ± 876
TYK2 2.7 ± 0.9 68‡
*All IC50 values were assayed at Km for ATP.
†All IC50 values were assayed at 1 mM of ATP.
‡Calculated IC50.
Table 2. Selective Inhibition of JAKs by INCB16562.
Enzyme % Inhibition
Alk 36
AurA 46
CDK1/CycB 1
CDK2/CycE 3
CHK1 0
CK2 10
C-Raf 5
CK2 10
EGFR 9
EphB4 8
FGFR3 0
FLT-1 8
FLT-3 0
GSK3a 9
HER2 0
HER4 0
IGF-1R 0
IKKa 6
IKKb 0
IR 3
JAK1 100
JAK2 100
JNK1 0
Lck 54
MAPK1 0
MAPK2 0
MEK1 0
Met 0
p70S6K 0
PDGFR 0
PDK1 10
PKA 0
PKBa 0
PKCa 0
PLK3 11
SGK 0
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Figure 2. INCB16562 inhibits cytokine-induced JAK/STAT signaling activities and cell growth. (A) INA-6 cells were cultured in the presence of
1 ng/ml of human IL-6 and treated with INCB16562 at indicated concentrations for 3 hours. Total lysates were subjected to Western blot
analysis for p-STAT3. The samemembranewaswashed and reprobed for STAT3. (B) INA-6 cellswere grown in the presenceof 1 ng/ml of IL-6
aswell as the drug at various concentrations for 3 days. Cell growth inhibition was calculated as a percentage of control from vehicle-treated
cells. This is a representative curve froman assay run in triplicate assay, and the IC50 value is averaged from20 independent assays. (C)MM1.
S, H929,U266, andRPMI8226 cellswere serum-stared for 4 hours and then pretreatedwith the drug at 0.3 or 1 μMfor 20minutes. Cellswere
stimulated with 10 ng/ml of IL-6 for 10 minutes, and total lysates were subjected to Western blot analysis for p-STAT3. Membranes were
washed and reprobed for STAT3. (D) MM1.S, H929, U266, and RPMI8226 cells were grown in regular culture medium in the presence of
thedrugat 0.3or 1μMfor 3days. The cell viabilitywasdeterminedandexpressedas thepercentageof inhibition relative to theDMSOcontrol.
(E) The primary bonemyeloma CD138+ plasma cells from aMMpatient were seeded in the presence of 10 ng/ml of IL-6 andwere incubated
with INCB16562 at the indicated concentrations for 3 days. In addition, cells treated with DMSO in the absence of IL-6 served as negative
controls. The cell viability was determined by CellTiter-Glo. The average fluorescent value from the negative controls was subtracted from all
the treated values indicated in the figure. The growth inhibition was expressed as percentage relative to the DMSO-treated cells. (F) Parental
TF-1 cells were serum-starved for 4 hours and then stimulated with human GM-CSF (2 ng/ml) for 10minutes after a 20-minute preincubation
with INCB16562 at 0.3 or 1 μM. Total lysates were used for Western blot analysis for p-STAT5. The same membrane was washed and re-
probed for STAT5. (G) Growing GM-CSF (2 ng/ml) stimulated parental TF-1 cells or TF-1–Bcr-Abl cells were cultured with the drug at various
concentrations for 3 days. Percent inhibition of cell proliferation was calculated relative to vehicle-treated cells. Error bars in all figures rep-
resent the SD of triplicates from one representative assay.
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and the cell viability was determined. We found that INCB16562 only
had marginally inhibitory effects on the growth of these cells at 1 μM in
the absence of IL-6, but we observed an approximately 70% increase in
cell growth in the DMSO-treated cells in the presence (vs absence) of
IL-6 (data not shown). However, the increased growth was completely
inhibited by INCB16562 in a dose-dependent manner (Figure 2E), in-
dicating that inhibition of the JAK/STATsignaling has significant effects
on the cytokine-stimulated growth of primary myeloma cells. No sig-
nificant effects of INCB16562 on the viability of normal B cells and
peripheral blood mononuclear cells were observed over the same dose
range as was tested in the plasma cells (data not shown).
To evaluate the cell-based selectivity of INCB16562, we compared
its effect on viable cell number in a pair of isogenic cell lines, parental
versusBcr-Abl–transduced TF-1 cells. Parental TF-1 cells are a cytokine-
dependent human erythroleukemic cell line. Human GM-CSF sup-
ports proliferation and viability of the parental TF-1 cells through
activation of the JAK2/STAT signaling pathway. Bcr-Abl expression in
these cells (TF-1–Bcr-Abl) renders them cytokine-independent because
their proliferation and survival are driven by the constitutively active Abl
kinase. Figure 2F shows that 300 nM of INCB16562 completely pre-
vented STAT5phosphorylation stimulated by the addition of 2 ng/ml of
human GM-CSF to TF-1 cells. As a result, the growth of the parental
TF-1 cells in the presence of GM-CSF was potently inhibited by
INCB16562 with an IC50 of 102 ± 36 nM, whereas the compound
had no effect on TF-1–Bcr-Abl cell growth (Figure 2G). Only at con-
centrations exceeding 4000 nM was a significant effect (>30% inhibi-
tion) observed. These results indicate that this compound is cell selective
for JAKs over the Abl kinase. The results also suggest that, at concen-
trations less than 4000 nM, INCB16562 does not significantly inhibit
other kinases or nonkinase enzymes that are critical for cell growth or
survival. Collectively, the cellular data, along with the enzyme data in
Tables 1 and 2, demonstrate that INCB16562 is a potent and selective
inhibitor of the JAK1 and JAK2 kinases in cells.
INCB16562 Induces Cell Death through Apoptosis in
INA-6 Cells
The cellular assays described above are unable to discern whether the
observed effects on viable cell number were due to decreased cell pro-
liferation, increased cell death, or both. Therefore, we determined the
effects of INCB16562 on the cellular DNA content by flow cytometry
analysis in IL-6–dependent INA-6 cells. As shown in Figure 3A, the
data indicate that INCB16562 alters the cell cycle distribution and
Figure 3. INCB16562 induces apoptosis and modest G2/M delay in INA-6 cells. All cells were grown in the presence of IL-6 (1 ng/ml). (A)
Cells were incubated with 0.8 μM of INCB16562 for 20 hours and then stained with PI for cell cycle analysis by flow cytometry. (B and C)
Cells were incubated with the drug at indicated concentrations for 24 hours. Apoptosis was then determined by flow cytometric analysis of
annexin V/PI staining and activation of caspase-3/7, -8, and -9. (D) Cells were treated with either 1 μM of INCB16562 or DMSO for 9 hours.
Total lysates were analyzed by Western blot for p-STAT3, cleavage of PARP (lower band), Mcl-1, Bcl-2, Bcl-XL, and β-actin (as control for
protein loading).
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induces a modest G2/M arrest in INA-6 cells treated with the com-
pound for 20 hours at a concentration sufficient to completely inhibit
STAT3 phosphorylation in these cells. Moreover, consistent with pub-
lished data that abrogation of the IL-6/JAK/STAT3 signaling pathway
induces apoptosis in INA-6 cells [26,27], we observed an increase in the
population of cells with a sub-G1 DNA content, indicative of apoptosis.
Looking more closely at the apoptotic effects of INCB16562, we then
treated INA-6 cells with increasing concentrations of the compound
and determined the percentage of apoptotic cells by flow cytometric
analysis of annexin V and PI-stained cells. As shown in Figure 3B,
the compound induced apoptosis in cells in a dose-dependent manner
suggesting the effects on viable cell number were due to both decreased
proliferation and increased cell death.
To explore the apoptoticmechanisms induced by blocking JAK/STAT
activation, we measured the activities of the apical caspases, caspase-8
and -9, as well as the effector caspases, caspase-3 and -7. A robust dose-
dependent activation of caspase-3/7 activity was observed after treatment
with INCB16562, in agreement with the annexin V data (Figure 3C).
Using isoform-specific assays, we observed that caspase-9 activity
was markedly increased with INCB16562 treatment compared with
minimal activation of caspase-8. These data clearly implicate activation
of the intrinsic apoptotic pathway in the death of INCB16562-treated
myeloma cells and suggest that unbalancing of the Bcl-2 family may
contribute to the observed effects. Therefore, we next analyzed the
levels of protein expression of various Bcl-2 family members in
INA-6 cells treated with 1 μMof INCB16562. As expected, the com-
pound markedly reduced p-STAT3 levels and induced cleavage of
PARP, another marker of caspase-dependent cell death (Figure 3D).
Although we observed no significant changes in Bcl-2 or Bcl-XL ex-
pression, Mcl-1 levels were dramatically reduced with INCB16562
treatment (Figure 3D). Because it was previously demonstrated that
IL-6–activated STAT3 can directly bind to the promoter and tran-
scriptionally upregulate Mcl-1 expression [30–32], the data here
suggest that reduced levels of this antiapoptotic protein caused by in-
hibition of STAT3 activity may have been at least partially responsible
for the observed apoptosis in INCB16562 treated INA-6 cells.
By searching for potential effects of INCB16562 on other signaling
pathways, we found that the compound at 1 μMdid not inhibit phos-
phorylation of ERK1/2 and Akt and had no effects on IκB-α phos-
phorylation or degradation (data not shown), indicating that
signaling through MAPK, Akt, or nuclear factor-κB is unlikely to be
directly involved in INCB16562-mediated apoptosis in INA-6 cells.
Thus, blockade of IL-6–induced JAK/STATsignaling by INCB16562
led to significant apoptosis in combination with a small G2/M delay in
INA-6 cells.
INCB16562 Abrogates the Protective Effects of IL-6 and Bone
Marrow Stromal Cells
The bone marrow microenvironment is rich in supportive growth
factors such as cytokines that are involved in support of the growth
and survival of myeloma cells [3]. We hypothesized that IL-6 and
other JAK-dependent cytokines were central to these protective effects.
To test this, we used an in vitro coculture model system assessing pro-
liferation of INA-6 cells on a confluent layer of human BMSCs [22,28].
Our previous data demonstrated that the IC50 value of INCB16562 in
blocking INA-6 cell proliferation when cocultured with BMSCs was
approximately 1.3- to 1.5-fold higher than the value obtained when
the cells were grown in the presence of 1 ng/ml of IL-6 alone (data
not shown), indicating that the compound had the ability to potently
inhibit JAK activity even in the presence of BMSCs. We first confirmed
that INCB16562 can potently inhibit STAT3 phosphorylation in the
INA-6 cells in the coculture system with BMSCs (Figure 4A). We next
used this coculture assay system to examine the effect of combination
of INCB16562 with other agents (bortezomib or melphalan) that have
demonstrated utility in treatment of myeloma. In a representative ex-
periment, 500 nM INCB16562 inhibited proliferation of INA-6 cells
by 55% in the presence of human BMSCs, whereas 10 nM of borte-
zomib had only a slight (5%) inhibitory effect (Figure 4B). However,
in combination, the proliferation was inhibited up to 82% suggesting
a synergistic response. A similar pattern of enhanced effect was also
observed in the combination between melphalan and INCB16562
(Figure 4C), although the single-agent activity of melphalan was more
impressive. These results demonstrate that the combination of bor-
tezomib or melphalan with INCB16562 can inhibit proliferation of
the myeloma cells more robustly than either drug alone in the presence
of BMSCs.
To better understand the nature of the potentiation of INCB16562
in antagonizing the protective effects of IL-6 or BMSCs, we moved to
another coculture model system in which JAK inhibition alone has lim-
ited effects on tumor cell proliferation. Dexamethasone (Dex) is widely
used in the treatment ofMM, and the humanMM1.Smyeloma cell line
is responsive to treatment with Dex in culture. However, it has been
shown that Dex-induced myeloma cell death can be abrogated by addi-
tion of IL-6 or coculture with BMSCs [9,33]. We hypothesized that
some, if not all, of the protective effects of coculture with BMSCs was
mediated by JAK-activating cytokines (e.g., IL-6), and we tested this
hypothesis by assessing growth inhibition of MM1.S cells in response
to Dex +/− INCB16562 in the presence or absence of IL-6 or BMSCs.
Previously, we demonstrated responsiveness of MM1.S cells to IL-6
by showing that the cells have low constitutive levels of p-STAT3 but
respond to IL-6 with a robust activation of JAK/STATand, importantly,
that this is reversed by addition of INCB16562 (Figure 2C ). In a rep-
resentative experiment, shown in Figure 4D, we first confirmed that
JAK/STATactivation was sufficient to convey resistance to Dex-treated
MM1.S cells. Under standard cell culture conditions, Dex alone in-
hibited MM1.S proliferation by approximately 70% compared with
vehicle-treated cells (lane 2). This growth inhibition was dramatically
decreased to approximately 30% when exogenous IL-6 was added to
the cell culture (lane 3), confirming that IL-6 provides a protective effect
toDex-treatedMM1.S cells. In a similar fashion, coculture with BMSCs
also protected cells from Dex-induced growth inhibition (lane 4; ∼16%
inhibition). Although the addition of pharmacologically active
(Figure 2C) levels of INCB16562 had no significant effect on the pro-
liferation of MM1.S cells (lane 1), it did completely revert the MM1.S
cells to a Dex-sensitive state when grownwith either IL-6 (lane 5; ∼70%
inhibition) or BMSC (lane 6; ∼66% inhibition). In aggregate, the results
suggest that activation of the JAK/STATsignaling by IL-6 and/or other
cytokines in the bone marrow microenvironment protects myeloma
cells from the antiproliferative effects of a variety of therapeutics and that
JAK1/2 inhibition can abrogate such protective mechanisms.
JAK Inhibition Potentiates the Growth Inhibitory Effects of
Bortezomib and Melphalan In Vivo
Wehave previously demonstrated that the INA-6.Tu1myeloma xeno-
graft model—a tumorigenic subclone of the INA-6 line—is responsive
to a pan-JAK inhibitor in vivo [22]. Here, we evaluated the ability
of INCB16562 to improve therapeutic responses to clinically relevant
therapies using this tumormodel. First, we established INA-6.Tu1 tumor
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xenografts in immunocompromised mice and assigned them into treat-
ment groups with similarmean tumor volumes. In the initial experiment,
treatment consisted of a single oral dose of vehicle or three different
dose levels of INCB16562 (5, 25, and 75 mg/kg). Tumors were har-
vested 4 hours after dosing and analyzed for levels of p-STAT3 after
normalizing samples for total protein (Figure 5A). Results from this
experiment demonstrated that a dose of 5 mg/kg was sufficient to mod-
estly reduce p-STAT3 levels in tumor tissue. A dose of 25 mg/kg was
determined to be the lowest dose tested that provided a marked inhibi-
tion of JAK/STAT in tumors for 4 hours or longer per dose. This dose
level was therefore chosen for subsequent experiments. Next, we treated
similar cohorts of tumor-bearing mice (n = 7 or 8 animals/group) with
INCB16562 (25 mg/kg, twice a day), melphalan (5 mg/kg, twice a
week), bortezomib (1.5 mg/kg, twice a week), or combinations of these
agents and compared tumor growth to vehicle-treated animals (Fig-
ure 5B). As a single agent, INCB16562 resulted in 85% inhibition of
tumor growth (day 23). Melphalan and bortezomib, administered at or
near their maximally tolerated dose levels, caused 91% and 14% growth
inhibition, respectively. The addition of INCB16562 resulted in a near-
complete inhibition of tumor growth when combined with either
melphalan (98%) or bortezomib (93%), demonstrating the ability of
a selective JAK1/2 inhibitor to potentiate the antitumor effects of these
relevant therapies in vivo. Importantly, the addition of a selective JAK
inhibitor to either treatment regiment was well tolerated, as assessed
by clinical observation and gross body weights (data not shown).
Discussion
Multiple lines of evidence support an important role for JAK signaling in
the initiation and progression of myeloma. In mice, constitutive expres-
sion of IL-6—a JAK-dependent cytokine—is sufficient to induce plasma-
cytomas [6,34]; conversely, IL-6 knockout mice are resistant to tumor
induction in an induced model of B-cell neoplasms [5]. These data are
complemented by the following observations: (1) studies in myeloma
patients demonstrate the presence of elevated levels of IL-6 and/or its
soluble receptor (sIL6R) [35], (2) BMSCs support the growth and
survival of myeloma cells, at least in part, by secreting a number of
JAK activating cytokines [3], and (3) cell autonomous dysregulation
of key regulatory feedback loops (e.g., SOCS-1 and SHP-1) has been
described in most myeloma patients [19,20], consistent with the
frequent finding of STAT3 activation in tumor samples [36,37]. In
aggregate, the evidence supports a fundamental role for JAK signaling
in the pathobiology of myeloma. JAK inhibitors can disrupt such
signaling cascades, and therefore, they may directly cause inhibition
of myeloma cell survival and/or proliferation and abrogate the protec-
tive environment resulting in sensitization of myeloma cells to relevant
drugs such as Dex, melphalan, or bortezomib.
Figure 4. INCB16562 enhances the effects of bortezomib and melphalan in INA-6 cells and sensitizes MM1.S to Dex in the presence of
BMSCs. (A) INA-6 cells (washed to remove IL-6) were seeded on top of confluent BMSCs and treated with various concentrations of
INCB16562. After 3 hours of incubation, the INA-6 cells were collected and the total lysates were analyzed by Western blot for p-STAT3.
The same membrane was washed and reprobed for STAT3. (B and C) INA-6 cells (washed to remove IL-6) were seeded on top of confluent
BMSCs. Cells were then treated for 3 days with the drugs listed in the figures, and proliferation of the INA-6 cells was determined by [3H]-
thymidine uptake (see Materials and Methods). The t test P value of the combination versus the sum of the net individual effect was calcu-
lated. *P ≤ .05 and statistically significant. (D) MM1.S cells were cultured in the absence or presence of either IL-6 or BMSCs for 3 days
with concomitant exposure to Dex in the presence or absence of INCB16562. Cell proliferation was determined by [3H]-thymidine uptake
in MM1.S cells. Error bars represent SD of triplicates in representative experiments.
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AG490 has been described and used as a JAK2 inhibitor in the lit-
erature for a long period, but our internal data and recent results from
Pedranzini et al. [28] strongly suggest that this compound is not a potent
or selective JAK inhibitor. Pyridone-6 and INCB20 are two recently
identified JAK inhibitors; however, these molecules are pan-JAK in-
hibitors that potently inhibit not only JAK1/2 but also JAK3 and/or
Tyk2, [22,28]. CP-690550 was described as an ATP-competitive
JAK3 inhibitor developed clinically as an immune suppressive agent
for the treatment of organ transplant recipients [38], but this compound
was recently found to have potent JAK1 and JAK2 activities in enzyme
assays as well as in cells [39,40]. In an effort to develop JAK2 selective
compounds for the treatment of MPDs, TG-101348 and XL-019 have
been recently described and are currently in clinical trials for MPDs.
Both inhibitors demonstrate a selectivity for JAK2 over JAK1, JAK3,
and Tyk2 [41,42], but their ability to effectively block JAK signaling
by cytokines such as IL-6 in myeloma cells may be hampered by their
lack of JAK1 activity. CYP387 is another newly characterized JAK
inhibitor with modest selectivity (∼10-fold) for JAK1/2 over JAK3 in
enzyme assays, and it has been shown to inhibit wild type JAK2 as well
as JAK2V617F in cellular assays [42], but this compound has yet to be
evaluated in myeloma models. Here, we describe the biochemical and
cellular activities of INCB16562, a novel, orally bioavailable, and potent
JAK1/2 selective inhibitor. We believe that, for the treatment of mye-
loma and a number of other neoplasias, JAK1/2 inhibition may be the
favored selectivity profile for a JAK inhibitor. This is based on the reli-
ance of either or both JAK1 and JAK2 in a number of homodimeric or
heterodimeric signaling complexes associated with different cytokine
and growth factors along with the potential liability of immune sup-
pression associated with JAK3 inhibition. Using this novel tool, we in-
vestigated the role of JAK1/2 signaling inmyeloma cell growth, survival,
and resistance to therapeutic treatment. INCB16562 potently inhibits
JAK1 and JAK2 at very low or subnanomolar concentrations and dem-
onstrates excellent selectivity within the JAK family (>300-fold selective
against JAK3 at 1 mM ATP) and against a broad panel of additional
kinases (Tables 1 and 2). The biochemical selectivity of INCB16562
wasmaintained in cells as demonstrated by its growth inhibitory potency
when tested in the cytokine/JAK–dependent INA-6 cells (Figure 2B)
and TF-1 cells compared with the isogenic TF-1–Bcr-Abl cells (Fig-
ure 2G) in which proliferation is supported by the Abl oncogene. Char-
acterization of the response of INA-6 cells to JAK inhibition revealed
effects on intracellular signaling pathways (Figure 2A), proliferation
(Figure 3A), and apoptosis (Figure 3, B–D), each occurring within the
same relative concentration range of INCB16562. The data implicate
the intrinsic/mitochondrial apoptotic program (caspase-3, -7, and -9)
as themajor effector pathway in the observed cell death.Mechanistically,
we observed a significant decrease in the expression levels ofMcl-1, a pro-
survival member of the Bcl-2 family, consistent with activation of the in-
trinsic apoptotic machinery. As Mcl-1 is a reported STAT3 target gene
and an important regulator of cell survival [30–32], we surmise this effect
contributes to the observed caspase-dependent cell death. We have been
unable to completely rule out a role of the extrinsic pathway owing to the
detectable though modest increases in caspase-8 activity (Figure 3C).
Importantly, we find that the ability of INCB16562 to inhibit
STAT phosphorylation in myeloma cells is not limited to the INA-6
Figure 5. INCB16562 inhibits growth of INA-6.Tu1 xenografts and enhances toxicity of bortezomib or melphalan in tumors. (A) Severe com-
bined immunodeficient micewere engraftedwith INA-6.Tu1 cells.When tumorswere established, animals were orally given a signal dose of
vehicle or INCB16562 at 5, 25, or 75 mg/kg (n = 3 animals/group). Tumors were harvested in 4 hours after dosing, and total lysates were
prepared from each tumor for Western analysis of p-STAT3. (B) Similarly, after INA-6.Tu1 tumors were established in mice, animals were
assigned into different groups (n = 7 or 8 animals/group) and treated with vehicle, INCB16562 (25 mg/kg, twice a day), melphalan (5 mg/kg,
twice aweek), bortezomib (1.5mg/kg, twice a week), or combination of these reagents for 12 days. Bortezomib or melphalan was given on
days 3, 5, 8, 10, and 12 after dosing of INCB16562. Antitumor effects of each drug alone or drugs in combination and individual bodyweight
of mice were measured and assessed two to three times each week. Error bars represent SD in each treatment group.
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cells. Indeed, four additional myeloma lines were studied and, although
they lacked high levels of basal p-STAT3, INCB16562 potently inhibi-
ted IL-6 stimulation of STAT3 phosphorylation (Figure 2C). Although
treatment of these cells with INCB16562 had limited or partial effects
on their survival, consistent with other reports [28], this is not unex-
pected because the process of isolating and maintaining cell lines under
various culture conditions can influence reliance on various growth
factors and their signaling pathways [26]. Nonetheless, these data
demonstrated that the myeloma cells can respond to cytokines in the
environment, such as in the bone marrow milieu, by activating STAT
signaling pathways in a JAK1/2–dependent manner. The relevance of
this cytokine-induced JAK signaling was demonstrated in experiments
in which myeloma cells were cultured either in the presence of BMSC
or recombinant IL-6 and then treated with clinically relevant therapeu-
tics in the presence or absence of INCB16562. These experiments show
that inhibition of JAK1/2 in either setting potentiates the effects of drug
treatment by antagonizing the protective effects of JAK/STATsignaling
and suggest that suboptimal clinical responses to treatment may be
limited by JAK activation. Indeed, we demonstrate for the first time that
inhibition of JAK1/2 improves the antitumor activity of two common
myeloma therapies, melphalan and bortezomib in an in vivo model
of myeloma.
Although there have been great strides made in the treatment of
myeloma during the past decade, there remains a need for new agents.
Accumulating data in the literature and our data described here suggest
that the benefit of multiple treatment regimens may be blunted because
of the activation of survival pathways such as JAK/STAT. Clearly, ex-
ploration of different drug combination regiments with a selective JAK
inhibitor is warranted.
References
[1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer
statistics. CA Cancer J Clin 58, 71–96.
[2] Kyle RA and Rajkumar SV (2008). Multiple myeloma. Blood 111, 2962–2972.
[3] Podar K, Chauhan D, and Anderson KC (2009). Bone marrow microenvironment
and the identification of new targets for myeloma therapy. Leukemia 23, 10–24.
[4] Zhang XG, Bataille R, Widjenes J, and Klein B (1992). Interleukin-6 dependence
of advanced malignant plasma cell dyscrasias. Cancer 69, 1373–1376.
[5] Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, and
Poli V (1997). Defective development of pristane-oil–induced plasmacytomas in
interleukin-6–deficient BALB/c mice. Am J Pathol 151, 689–696.
[6] Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K,
Hirano T, and Kishimoto T (1992). Generation of plasmacytomas with the chro-
mosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci
USA 89, 232–235.
[7] KawanoMM,Mihara K, Huang N, Tsujimoto T, and Kuramoto A (1995). Differ-
entiation of early plasma cells on bone marrow stromal cells requires interleukin-6
for escaping from apoptosis. Blood 85, 487–494.
[8] Klein B, Zhang XG, Lu ZY, and Bataille R (1995). Interleukin-6 in human
multiple myeloma. Blood 85, 863–872.
[9] Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, and Epstein J
(1994). Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood 84, 3063–3070.
[10] Lichtenstein A, Tu Y, Fady C, Vescio R, and Berenson J (1995). Interleukin-6
inhibits apoptosis of malignant plasma cells. Cell Immunol 162, 248–255.
[11] Lichtenstein A, Berenson J, Norman D, ChangMP, and Carlile A (1989). Produc-
tion of cytokines by bone marrow cells obtained from patients with multiple
myeloma. Blood 74, 1266–1273.
[12] Chauhan D, UchiyamaH, Akbarali Y, UrashimaM, Yamamoto K, Libermann TA,
and Anderson KC (1996). Multiple myeloma cell adhesion–induced interleukin-6
expression in bone marrow stromal cells involves activation of NF-kappa B. Blood
87, 1104–1112.
[13] Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, and
Anderson KC (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-
activated protein kinase cascade. J Immunol 159, 2212–2221.
[14] Berger LC, Hawley TS, Lust JA, Goldman SJ, and Hawley RG (1994). Tyrosine
phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-
stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 202, 596–605.
[15] Hideshima T, Bergsagel PL, Kuehl WM, and Anderson KC (2004). Advances in
biology of multiple myeloma: clinical applications. Blood 104, 607–618.
[16] Baker SJ, Rane SG, and Reddy EP (2007). Hematopoietic cytokine receptor signal-
ing. Oncogene 26, 6724–6737.
[17] Levine RL, Pardanani A, Tefferi A, and Gilliland DG (2007). Role of JAK2 in the
pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7,
673–683.
[18] Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS,
Metcalf D, Hilton DJ, and Nicola NA (1999). Mutational analyses of the SOCS
proteins suggest a dual domain requirement but distinct mechanisms for inhibition
of LIF and IL-6 signal transduction. EMBO J 18, 375–385.
[19] Galm O, Yoshikawa H, Esteller M, Osieka R, and Herman JG (2003). SOCS-1, a
negative regulator of cytokine signaling, is frequently silenced by methylation in
multiple myeloma. Blood 101, 2784–2788.
[20] Chim CS, Fung TK, Cheung WC, Liang R, and Kwong YL (2004). SOCS1 and
SHP1 hypermethylation in multiple myeloma: implications for epigenetic activa-
tion of the Jak/STAT pathway. Blood 103, 4630–4635.
[21] Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S,
Davies FE, Chauhan D, et al. (2001). Adherence of multiple myeloma cells to
bone marrow stromal cells upregulates vascular endothelial growth factor secretion:
therapeutic applications. Leukemia 15, 1950–1961.
[22] Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K,
Catley L, Hideshima T, Chauhan D, et al. (2009). Janus kinase inhibitor INCB20
has antiproliferative and apoptotic effects on human myeloma cells in vitro and
in vivo. Mol Cancer Ther 8, 26–35.
[23] O’Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL, Buckley RH,
Changelian P, and Candotti F (2004). Jak3 and the pathogenesis of severe com-
bined immunodeficiency. Mol Immunol 41, 727–737.
[24] Burger R, Günther A, Bakker F, Schmalzing M, Bernand S, Baum W, Duerr B,
Hocke GM, Steininger H, Gebhart E, et al. (2001). Gp130 and ras mediated
signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for
plasmacytoma. Hematol J 2, 42–53.
[25] Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, and Ashcroft FM
(2000). A novel method for measurement of submembrane ATP concentration.
J Biol Chem 275, 30046–30049.
[26] Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT, and
Nordan RP (2000). Constitutive activation of STAT3 is associated with the acqui-
sition of an interleukin 6–independent phenotype by murine plasmacytomas and
hybridomas. Blood 96, 3514–3521.
[27] Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, and
Gramatzki M (1998). Human herpesvirus type 8 interleukin-6 homologue is
functionally active on human myeloma cells. Blood 91, 1858–1863.
[28] Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, BornmannW,
and Bromberg J (2006). Pyridone 6, a pan-Janus–activated kinase inhibitor, in-
duces growth inhibition of multiple myeloma cells. Cancer Res 66, 9714–9721.
[29] Schwab G, Siegall CB, Aarden LA, Neckers LM, and Nordan RP (1991). Char-
acterization of an interleukin-6–mediated autocrine growth loop in the human
multiple myeloma cell line, U266. Blood 77, 587–593.
[30] Puthier D, Bataille R, and Amiot M (1999). IL-6 up-regulates mcl-1 in human
myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J
Immunol 29, 3945–3950.
[31] Epling-Burnette PK, Liu JH,Catlett-Falcone R,Turkson J,OshiroM,Kothapalli R,
Li Y, Wang JM, Yang-Yen HF, Karras J, et al. (2001). Inhibition of STAT3 sig-
naling leads to apoptosis of leukemic large granular lymphocytes and decreased
Mcl-1 expression. J Clin Invest 107, 351–362.
[32] Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA,
and Gores GJ (2005). Interleukin 6 upregulates myeloid cell leukemia-1 expression
through a STAT3 pathway in cholangiocarcinoma cells.Hepatology 42, 1329–1338.
[33] Grigorieva I, Thomas X, and Epstein J (1998). The bone marrow stromal environ-
ment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol
26, 597–603.
[34] DederaDA,UrashimaM,ChauhanD, LeBrunDP, BronsonRT, andAndersonKC
(1996). Interleukin-6 is required for pristane-induced plasma cell hyperplasia in
mice. Br J Haematol 94, 53–61.
Neoplasia Vol. 12, No. 1, 2010 Inhibition of JAK1 and JAK2 in Multiple Myeloma Li et al. 37
[35] Bataille R, JourdanM, Zhang XG, and Klein B (1989). Serum levels of interleukin
6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell
dyscrasias. J Clin Invest 84, 2008–2011.
[36] Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R,
Ciliberto G, Moscinski L, Fernandez-Luna JL, Nuñez G, et al. (1999). Constitu-
tive activation of Stat3 signaling confers resistance to apoptosis in human U266
myeloma cells. Immunity 10, 105–115.
[37] Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M,
Schaich R, Höfler H, and Fend F (2003). Analysis of signal transducer and acti-
vator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation
and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162,
1449–1461.
[38] Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH,
Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, et al. (2003). Prevention of
organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302,
875–878.
[39] Williams NK, Bamert RS, Patel R, Wang C, Walden PM, Wilks AF, Fantino E,
Rossjohn J, and Lucet IS (2009). Dissecting specificity in the Janus kinases: the
structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein
tyrosine kinase domains. J Mol Biol 387, 219–232.
[40] Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z,
Prchal J, Cortes JE, Kantarjian HM, and Verstovsek S (2008). The JAK kinase
inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells
carrying the JAK2V617F mutation. Cancer Sci 99, 1265–1273.
[41] Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M,
McDowell EP, Levine RL, Doukas J, et al. (2008). Efficacy of TG101348, a selec-
tive JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced poly-
cythemia vera. Cancer Cell 13, 311–320.
[42] Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, and Tefferi A (2009).
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity
and preclinical studies using cell lines and primary cells from polycythemia vera
patients. Leukemia 23, 1441–1445.
38 Inhibition of JAK1 and JAK2 in Multiple Myeloma Li et al. Neoplasia Vol. 12, No. 1, 2010
